Bluebird Ventures
VC Fund
Palo Alto, United States
BlueBird Ventures is a venture capital fund that is managed by Sutter Hill Ventures.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Bluebird Ventures invests in
BiotechnologyHealth CareTherapeuticsLife ScienceMedical
Stages Bluebird Ventures invests in
Series BSeries ASeries CSeries DSeries E
Countries Bluebird Ventures invests in
United StatesThe Netherlands
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jeff Bird
|
|||
Investment Focus
Industry
- Biotechnology 5 (45%)
- Health Care 4 (36%)
- Therapeutics 3 (27%)
- Life Science 2 (18%)
- Medical 1 (9%)
Stage
- Series B 4 (36%)
- Series A 3 (27%)
- Series C 1 (9%)
- Series D 1 (9%)
- Series E 1 (9%)
Country
- United States 5 (45%)
- The Netherlands 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jeff Bird
Founder and Managing Director
|
Founder and Managing Director | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Foresight Diagnostics
|
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $33M / Series B / Jul 30, 2024 | |
Procyrion
|
Procyrion develops technology solutions and offers a catheter-based circulatory support technologies. One in five adults over the age of 40 will develop heart failure in his or her lifetime. For the sickest patients, only 1% receive treatment annually due to scarcity, cost, and high risk of current solutions.Procyrion, has developed a solution:Aortix is a circulatory support pump implanted without surgery. Thinner than a #2 pencil, a cardiologist can implant Aortix through a catheter in the leg, deploying it between the heart and the kidneys to unload the failing heart and perfuse vital organs. This first-in-class device allows the heart to rest and heal while correcting the fluid imbalance.The company was founded in 2005 and is based in Houston, Texas. | $47.7M / Series E / Feb 05, 2024 | |
|
Foresight Diagnostics
|
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $58.8M / Series B / Apr 27, 2023 | |
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $270M / Series C / May 16, 2022 | |
Leyden Labs
|
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $140M / Series B / Jan 25, 2022 | |
|
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $100M / Series B / Jul 14, 2021 | |
|
Foresight Diagnostics
|
Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $12.5M / Series A / Dec 12, 2020 | |
Nutcracker Therapeutics
|
Nutcracker Therapeutics is a biotech company that develops and produces mRNA therapeutics on its proprietary, microfluidic, and biochip-based platform. The company specializes in a fully-integrated system for the production of mRNA-therapeutics at the push of a button that enables scalable on-demand experimental and manufacturing capacity, therebyenabling healthcare companies to produce complex multimodal therapeutics at point of care.Nutcracker Therapeutics combines the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to develop a proprietary miniaturized platform that enables the rapid discovery, development, and manufacturing of mRNA therapies and vaccines. Its ACORN platform is a first-of-its-kind, computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips.Igor Khandros and Benjamin Eldridge established the company in Emeryville, California in 2018. | $60M / Series B / Sep 23, 2020 | |
|
Kriya Therapeutics
|
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $80.5M / Series A / May 12, 2020 | |
Epirium Bio
|
Epirium Bio is a biopharmaceutical company based in San Diego, is developing a small molecule platform targeting improvements in muscle strength, tissue regeneration, and mitochondrial function. | $85M / Series A / Dec 18, 2019 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Life Science Investors
6,823 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Bluebird Ventures invest in?
Bluebird Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bluebird Ventures?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Bluebird Ventures?
The team at Bluebird Ventures includes Jeff Bird (Founder and Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
